Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorSeung-Jung Park
About this trial
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
coronary disease amenable to percutaneous coronary intervention (PCI)
no clinical and lesion limitations
Disqualifiers
patients with a mixture of several DES
terminal illness with life expectancy less than 1 year
patients with cardiogenic shock
Trial population
consecutive patients amenable to PCI
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
50,000 Participants
are grouped into 27 trial groups27
Trial groupsSee each trial group below.
Group A: DESSIAN
Group B: K-XIENCE
Group C: GENOUS
Group D: ELEMENT
Group E: PRIME
Group F: NOBORI
Group G: INTEGRITY
Group H: XPEDITION
Group I: BIOMATRIX
Group J: CILOTAX
Group K: DEB
Group L: DESYNE
Group M: PREMIER
Group N: ORSIRO
Group O: ONYX
Group P: BVS
Group Q: BVS AMI
Group R: Ultimaster
Group S: Synergy
Group T: Biofreedom
Group U: Firehawk
Group V: DESyne X2
Group W: Sierra
Group X: Tansei
Group Y: Synergy XD and Synergy Megatron™
Group Z: Xience-Skypoint
Group [: Coroflex ISAR NEO
Trial outcomes
Primary outcomes
1
Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
Time frame
at 12 months post procedureSecondary outcomes
1
Death (all-cause and cardiac)
Time frame
at 12 months and annually up to 5 years2
Myocardial infarction
Time frame
at 12 months and annually up to 5 years3
Stent thrombosis
Time frame
at 12 months and annually up to 5 years4
Target-lesion and target-vessel revascularization
Time frame
at 12 months and annually up to 5 yearsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Korean centresRecruiting Multiple LocationsSouth Korea
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Seung-Jung Park
Lead sponsor
CardioVascular Research Foundation, Korea
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator
Source ClinicalTrials.gov